Corcept Therapeutics (CORT) director shifts shares to family trusts

Rhea-AI Filing Summary

Corcept Therapeutics director James N. Wilson reported several internal movements of Corcept common stock among family-related entities on December 12, 2025. A family trust disposed of 400,000 shares as a gift at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust.

Two 2025 grantor retained annuity trusts each received 200,000 shares without consideration and are reported as indirectly holding 200,000 shares apiece. The report also lists 901,067 shares of Corcept common stock held indirectly through James and Pamela Wilson Family Partners, over which Wilson has voting power pursuant to voting agreements while disclaiming beneficial ownership except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		G		400,000	D	$0.00	1,045,168	I	James N. Wilson and Pamela D. Wilson Trust(1)
Common Stock	12/12/2025		J(2)		200,000	A	$0.00	200,000	I	James N. Wilson 2025 Grantor Retained Annuity Trust.(3)
Common Stock	12/12/2025		J(4)		200,000	A	$0.00	200,000	I	Pamela D. Wilson 2025 Grantor Retained Annuity Trust.(5)
Common Stock								901,067	I	James and Pamela Wilson Family Partners(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

2. Transfer of shares without consideration to James N. Wilson 2025 Grantor Retained Annuity Trust.

3. On December 12, 2025, the Reporting Person contributed 200,000 shares to a grantor retained annuity trust for the benefit of himself, Pamela D. Wilson and his two children.

4. Transfer of shares without consideration to Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

5. On December 12, 2025, the Reporting Person contributed 200,000 shares to a grantor retained annuity trust for the benefit of Pamela D. Wilson, the Reporting Person and her two children.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corcept Therapeutics (CORT) disclose for James N. Wilson?

James N. Wilson, a director of Corcept Therapeutics, reported a 400,000-share gift of Corcept common stock and related transfers among family-related entities on December 12, 2025.

How many Corcept shares were transferred from the James N. and Pamela D. Wilson Trust?

The filing shows the James N. Wilson and Pamela D. Wilson Trust disposed of 400,000 Corcept common shares at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly.

What holdings are reported for the 2025 grantor retained annuity trusts?

Each of the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust is reported as indirectly holding 200,000 Corcept common shares.

Were these Corcept share movements sales for cash on the open market?

No. The transactions are described as a gift and transfers of shares without consideration to family trusts at a reported price of $0.00 per share.

How many Corcept Therapeutics shares are reported as indirectly owned after these transactions?

The report lists 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust, 200,000 shares in each of the two 2025 grantor retained annuity trusts, and 901,067 shares held indirectly through James and Pamela Wilson Family Partners.

What beneficial ownership position does James N. Wilson report over these Corcept shares?

He has voting power over shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements, and disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.